From biased signalling to polypharmacology: unlocking unique intracellular signalling using pepducins.

For over a decade, pepducins have been utilized to develop unique pharmacological profiles that have been particularly challenging for traditional drug discovery methods. It is becoming increasingly clear that these cell-penetrating lipopeptides can access receptor conformations that are currently not accessible through orthosteric targeting. This review addresses the emerging concepts in the development of pepducins including the elicitation of biased signalling, pepducin polypharmacology and recent insight into their mechanism of action.

[1]  R. Mullins,et al.  β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.

[2]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[3]  P. Ponikowski,et al.  Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). , 2015, JACC. Heart failure.

[4]  E. Bel.  Clinical Practice. Mild asthma. , 2013, The New England journal of medicine.

[5]  A. Prochiantz,et al.  Cell-Penetrating Peptides , 2021, Methods in Molecular Biology.

[6]  J. Violin,et al.  Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. , 2011, Circulation research.

[7]  Robert C. Glen,et al.  Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist , 2015, Hypertension.

[8]  D. Sibley,et al.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor. , 2015, ACS chemical neuroscience.

[9]  Angela D. Wilkins,et al.  Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor , 2015, Proceedings of the National Academy of Sciences.

[10]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[11]  C. Dahlgren,et al.  A neutrophil inhibitory pepducin derived from FPR1 expected to target FPR1 signaling hijacks the closely related FPR2 instead , 2015, FEBS letters.

[12]  M. J. Chalmers,et al.  Dynamics of the beta2-adrenergic G-protein coupled receptor revealed by hydrogen-deuterium exchange. , 2010, Analytical chemistry.

[13]  J. Benovic,et al.  Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein , 2013, Proceedings of the National Academy of Sciences.

[14]  A. Kuliopulos,et al.  Turning Receptors On and Off with Intracellular Pepducins: New Insights into G-protein-coupled Receptor Drug Development* , 2012, The Journal of Biological Chemistry.

[15]  L. Luttrell.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. , 2014, Molecular endocrinology.

[16]  Shuxing Zhang,et al.  Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.

[17]  M. Dean,et al.  Structural analogues of smoothened intracellular loops as potent inhibitors of Hedgehog pathway and cancer cell growth. , 2007, Journal of medicinal chemistry.

[18]  Ping Zhang,et al.  Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics. , 2015, Methods in molecular biology.

[19]  S. Ben‐Sasson,et al.  Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). , 2003, Blood.

[20]  Violeta I. Pérez-Nueno,et al.  Studying the binding interactions of allosteric agonists and antagonists of the CXCR4 receptor. , 2015, Journal of molecular graphics & modelling.

[21]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[22]  N. Kaneider,et al.  Reversing systemic inflammatory response syndrome with chemokine receptor pepducins , 2005, Nature Medicine.

[23]  J. Benovic,et al.  Interdicting Gq Activation in Airway Disease by Receptor-Dependent and Receptor-Independent Mechanisms , 2016, Molecular Pharmacology.

[24]  J. Violin,et al.  beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. , 2009, The Journal of clinical investigation.

[25]  Lynn R. Webster,et al.  Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers , 2014, PAIN®.

[26]  A. Kuliopulos,et al.  Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Michel Bouvier,et al.  Development and Characterization of Pepducins as Gs-biased Allosteric Agonists*♦ , 2014, The Journal of Biological Chemistry.

[28]  A. Kuliopulos,et al.  Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. , 2011, Methods in molecular biology.

[29]  T. S. Kobilka,et al.  Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling , 2015, Cell.

[30]  Lisa Nguyen,et al.  Selectively Engaging β-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance , 2010, Journal of Pharmacology and Experimental Therapeutics.

[31]  Ü. Langel,et al.  Cell-Penetrating Peptides , 2000, Methods in Molecular Biology.

[32]  A. Bohm,et al.  Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics* , 2015, The Journal of Biological Chemistry.

[33]  Pallavi Sachdev,et al.  Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4. , 2011, Journal of the American Chemical Society.

[34]  U. Holzgrabe,et al.  Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  C. Lindsley,et al.  G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. , 2008, ACS chemical biology.

[36]  Eric Trinquet,et al.  Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy , 2012, Proceedings of the National Academy of Sciences.

[37]  K. Schrör,et al.  Inhibition of platelet thromboxane receptor function by a thrombin receptor–targeted pepducin , 2003, Nature Medicine.

[38]  M. Kotlikoff,et al.  Molecular mechanisms of beta-adrenergic relaxation of airway smooth muscle. , 1996, Annual review of physiology.

[39]  T. Kenakin,et al.  Inverse, protean, and ligand‐selective agonism: matters of receptor conformation , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Pallavi Sachdev,et al.  Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells , 2010, Proceedings of the National Academy of Sciences.

[41]  A. Kuliopulos,et al.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation , 2002, Nature Medicine.

[42]  Guodong Liu,et al.  A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[43]  J. Benovic,et al.  Regulation of CXCR4 signaling. , 2007, Biochimica et biophysica acta.

[44]  Kurt Wüthrich,et al.  Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.

[45]  P. Dorinsky,et al.  The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.